Skip to main content

Table 1 Patient characteristics

From: A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

Age, median (range) (years)

57 (46–75)

Performance status, n

 0

15

 1

4

  ≥ 2

0

Histology, n

 High-grade serous

12

 Endometrial

1

 Clear cell

4

 Others

2

Previous platinum-based chemotherapy

 1

14

 2

5

Platinum-free interval (months)

 0

7

 1–2

1

 3–4

5

 5

6